Catalyst Brief

← Calendar

Readoutin 13d

Adverum Biotechnologies, Inc. — Ixo-vec

Phase 3 primary completion: Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration.

Date
Dec 2026
Type
Readout
Indication
Neovascular Age-Related Macular Degeneration (nAMD)

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.